Asceneuron appoints experienced CNS clinician Dr Eric Yuen to the Board of Directors
Posted on 20.05.2019 in Company Highlight, News
20.5.2019 – Asceneuron, an emerging leader in the development of orally bioavailable modulators of tau for the treatment of neurodegenerative diseases, today announces the appointment of Dr Eric Yuen to its Board of Directors.
